Genitourinary Cancer,RCC (Renal Cell Carcinoma) Axitinib + Neoadjuvant Tislelizumab in Localized CcRCC Mar 11, 2024
Bladder Cancer,Genitourinary Cancer APL-1202 +Tislelizumab: Exceeding pCR Rate Thresholds Mar 07, 2024
Genitourinary Cancer,RCC (Renal Cell Carcinoma) NIVO+IPI Over SUN in aRCC : Long Term Survival Benefits Mar 05, 2024
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Tislelizumab Neoadjuvant Monotherapy in High-Risk UTUC Feb 26, 2024
Bladder Cancer,Genitourinary Cancer Neoadjuvant NIVO & Nab-ABX in MIBC: NURE-Combo Study Feb 22, 2024
Genitourinary Cancer,RCC (Renal Cell Carcinoma) NIVO SC vs IV: Efficacy and Safety in CcRCC Feb 20, 2024
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Belzutifan vs Everolimus: Improved QoL in RCC Feb 20, 2024
